ANTEOTECH LTD — AGM Information 2014

Nov 9, 2014

==> picture [261 x 133] intentionally omitted <==

==> picture [459 x 129] intentionally omitted <==

Anteo Diagnostics (ASX:ADO) Annual General Meeting 10th November 2014 Welcome

==> picture [720 x 152] intentionally omitted <==

----- Start of picture text -----

The Surface Science Company
----- End of picture text -----

MEETING FORMAT

==> picture [148 x 78] intentionally omitted <==

 Introductions

 Formal Resolutions

• CEO Report

• Other Business

• Meeting Close

Anteo Diagnostics

2

Introductions

==> picture [148 x 78] intentionally omitted <==

Anteo Diagnostics Limited – Present

 Mark Bouris– Non Executive Chairman

 Geoff Cumming – CEO

 Richard Martin – Executive Director

 Sandra Andersen – Non Executive Director  John Hurrell – Non Executive Director

Grant Thornton

• Matthew Bell – Partner

Anteo Diagnostics

3

==> picture [148 x 78] intentionally omitted <==

Formal Resolutions

Resolution 1: Adoption of Directors’ Remuneration Report

Resolution 2: Re- Election of Director (Mr Richard Martin) Resolution 3: Approval of 10% Placement Capacity Resolution 4: Issue of Securities under Executive/Employee Share Plan Resolution 5: Issue of 5,000,000 Options (Mr Mark Bouris) Resolution 6: Issue of 6,000,000 Options (Mr Richard Martin)

Resolution 7: Issue of 3,000,000 Options (Ms Sandra Andersen) Resolution 8: Issue of 3,000,000 Options (Dr John Hurrell)

Anteo Diagnostics

4

RESOLUTIONS – PROXY COUNT

==> picture [148 x 78] intentionally omitted <==

	Description	For	Against	Open	Excluded	Abstain	Totals
Resolution 1	Adoption of Directors’ Remuneration Report	215,294,159	3,717,929	20,000	17,500,000	2,432,978	238,965,066
Resolution 2	Re- Election of Director (Mr Richard Martin)	222,925,455	8,059,713	5,995,120	0	1,984,778	238,965,066
Resolution 3	Approval of 10% Placement Capacity	208,745,197	20,758,167	9,249,404	0	212,298	238,965,066
Resolution 4	Issue of Securities under Executive/Employee Share Plan	202,329,654	6,663,010	9,164,204	17,500,000	3,308,198	238,965,066
Resolution 5	Issue of 5,000,000 Options (Mr Mark Bouris)	200,766,002	9,858,951	8,571,904	17,500,000	2,268,209	238,965,066
Resolution 6	Issue of 6,000,000 Options (Mr Richard Martin)	82,007,782	15,941,351	8,571,904	130,176,320	2,267,709	238,965,066
Resolution 7	Issue of 3,000,000 Options (Ms Sandra Andersen)	197,418,502	13,206,451	8,571,904	17,500,000	2,268,209	238,965,066
Resolution 8	Issue of 3,000,000 Options (Dr John Hurrell)	200,585,202	10,039,751	8,571,904	17,500,000	2,268,209	238,965,066

Anteo Diagnostics

5

==> picture [261 x 133] intentionally omitted <==

==> picture [459 x 129] intentionally omitted <==

Anteo Diagnostics (ASX:ADO) Annual General Meeting CEO UPDATE

==> picture [720 x 152] intentionally omitted <==

----- Start of picture text -----

The Surface Science Company
----- End of picture text -----

2014 Review

==> picture [148 x 78] intentionally omitted <==

• Commercialisation

• Technical Development

• Internal Skill Set - Personnel

• Corporate Activities

Anteo Diagnostics

7

Commercialisation

Headline Projects

• BBI

• Achieved Phase 3 goals

• Require better sensitivity

• • POC 1

• Successful delivery

• Expanded scope of study

AMG Products

• Maturity recognition with customers

• Broad interest – tier 1 companies

• Delivering new product per quarter

==> picture [148 x 78] intentionally omitted <==

==> picture [113 x 171] intentionally omitted <==

==> picture [238 x 210] intentionally omitted <==

Anteo Diagnostics

8

Commercialisation

==> picture [148 x 78] intentionally omitted <==

Global Presence

• Permanent BD capability in 3 time zones

• Tina - Europe

• Josh - Americas

• Rachel – Asia Pacific

Paid Research & Collaboration

Expanding demands

• Diagnostics

• Particles

• Plates

• Plastics and other surfaces

• Separations – magnetic particles

• Medical products – coatings

• Industrial - silica

~~Commercialisation: New elements and an extended asset base~~

Anteo Diagnostics

Technical Development

==> picture [148 x 78] intentionally omitted <==

New Mix&Go Formulations

• Solidify short-term opportunities

• Open up full spectrum of uses

==> picture [90 x 75] intentionally omitted <==

----- Start of picture text -----

2012
R & d
----- End of picture text -----

• Reconfirm concepts upon which Mix&Go is founded

Moved from Research to Production Capability

• Base Mix&Go components

• End products

• Developed ‘know how’ that further protects patents

==> picture [90 x 75] intentionally omitted <==

----- Start of picture text -----

2014
r & D
----- End of picture text -----

The Surface You Want on the Surface You Have Expanded Capability: Mix&Go now offers optimal results on both Hydrophilic & Hydrophobic Surfaces

Anteo Diagnostics

10

Technical Development

==> picture [148 x 78] intentionally omitted <==

Signal Amplification

• Here & now extending life and utility of lateral flow devices

• Generally applicable to assays

Application Diversity

==> picture [502 x 176] intentionally omitted <==

----- Start of picture text -----

Plastics
Plates Glass
Particles
1 [st] gen 1 [st gen] &
Mix&Go Ceramics
2 [nd gen]
Metals
----- End of picture text -----

Technical Trifecta: ex nded technol pa ogy base, more applications, addresses target markets.

Anteo Diagnostics

11

Internal Skill Set (Personnel)

==> picture [148 x 78] intentionally omitted <==

New People with the Expertise and Experience to Expand

• Manufacture desired Mix&Go

• From base components

• For specific purposes

• Production capability

• IVD & POC depth to R&D team especially lateral flow

• Techno-commercial skill at tier 1 IVD level

Ability to capably address different surface types used in a broad array of systems

Developed robust internal administration infrastructure and quality control

Im lementation: Ri ht Peo le Ri ht p g p , g Place, Right Time.

Anteo Diagnostics

12

Corporate Perspective

==> picture [148 x 78] intentionally omitted <==

Operational Subsidiary Change of Name Bio-Layer is now Anteo Technologies

• To better reflect our brand’s product, patents & potential

• Avoids market perception of ‘just diagnostics’

Build Capability and Asset Base

• Depth and breadth of products

• Core company skill sets

==> picture [293 x 137] intentionally omitted <==

Anteo Diagnostics

13

Corporate Perspective

==> picture [148 x 78] intentionally omitted <==

Strategic outlook: control destiny

• Placement

• Financial security

• Opportunity to build asset base and capability

• Own AMG product range

Minimise Timeframes to Business Goals

• Engaged advisor

• Searching alternatives (incl M&A)

==> picture [210 x 168] intentionally omitted <==

~~Commercial Value from Patented Technology~~

Anteo Diagnostics

14

==> picture [148 x 78] intentionally omitted <==

Thank you very much for your attendance today.

==> picture [511 x 351] intentionally omitted <==

Anteo Diagnostics

15